{
  "header.languageSelect": "Select Language",
  "header.english": "English",
  "header.spanish": "Español",
  "languages": {
    "english": "English",
    "spanish": "Español"
  },
  "header": {
    "languageSelect": "Select Language",
    "english": "English",
    "spanish": "Español",
    "title": "CC3S - Cervical Cancer Screening Scenario Simulator"
  },
  "footer": {
    "centerForGlabalHealth": "Center for Global Health",
    "atThe": "at the",
    "atTheNationalCancerInstitute": "National Cancer Institute",
    "contactInformation": "CONTACT INFORMATION",
    "contactUs": "Contact Us",
    "policies": "POLICIES",
    "accessibility": "Accessibility",
    "disclaimer": "Disclaimer",
    "FOIA": "FOIA",
    "HHSVulnerabilityDisclosure": "HHS Vulnerability Disclosure",
    "moreInformation": "MORE INFORMATION",
    "usDepartmentOfHealthAndHumanServices": "U.S. Department of Health and Human Services",
    "nationalInstitutesOfHealth": "National Institutes of Health",
    "nationalCancerInstitude": "National Cancer Institute",
    "usaGov": "USA.gov",
    "nihSlogan": "NIH ... Turning Discovery Into Health "
  },
  "navbar": {
    "home": "Home",
    "runScenario": "Run Scenario",
    "runScenarioResults": "Run Scenario - Results",
    "compareScenarios": "Compare Scenarios",
    "about": "About"
  },
  "home": {
    "introdution": "Explore clinical and epidemiological outcomes for target populations with our screening impact assessment tool.",
    "whatIsCC3S": "What is CC3S?",
    "whatIsCC3SDes": "Cervical Cancer Screening Scenario Simulator (CC3S) is a scenario tool developed by the National Cancer Institute Center for Global Health (NCI/CGH) to assist health officials and/or providers planning and understanding their national cervical cancer screening program at different levels of the health system. You can use this tool to visualize how effective a program might be and what resources would be required depending on variable options of screening coverage, frequency, tests utilized, test accuracy and follow-up in your local context. This tool is meant to facilitate conversations amongst partners.",
    "beforeYouStartTitle": "Before you start, please remember:",
    "insight": "Insight",
    "insightDes": "CC3S is an easy-to-use tool created to inform and facilitate decision-making to create feasible cervical cancer screening programs. Please note that the figures and numbers are simplified and not meant to precisely reflect real-world planning. This tool is meant to be used for comparing assumptions and strategies for cervical cancer screening programs. CC3S considers the resource and impact of only one screening round.",
    "judgmentFree": "Judgment-free",
    "jusdgementFreeDes": "There is no right or wrong answer. Feel free to test your assumptions and consider screening and triage options that could help design the most appropriate and feasible screening strategy for your unique setting.",
    "engage": "Engage",
    "engageDes": "It is natural to encounter many questions about your results. We encourage you to use the findings as discussion material with your team(s) and key local partners.",
    "des0": "Are you ready to discover CC3S? Navigate to the ",
    "des0Continued": " tab to start planning your cervical cancer prevention strategy!",
    "des1": "If you have any questions or technical issues, please select ",
    "des1Continued": "below.",
    "emphasize": "This tool is best used with a trained facilitator to guide you through the decision-making process, but you are welcome to use it on your own. Please",
    "withQuestions": "with questions.",
    "desLink0": "For more information, navigate to the",
    "resourceLink": "Resources",
    "desLink1": "tab for key definitions, descriptions, and evidence for scenario parameters in CC3S."
  },
  "general": {
    "ccpTitle": "CC3S - Cervical Cancer Screening Scenario Simulator",
    "﻿Key": "English",
    "ccpLongDes": "Cervical Cancer Screening Scenario Simulator",
    "welcome": "Welcome to CC3S",
    "enterValue0t100HelpText": "Enter a value between 0 and 100.",
    "screening": "Screening",
    "screeningTestLabel": "Screening Test",
    "triage": "Triage",
    "triageTestLabel": "Triage Test",
    "diagnosis": "Diagnosis",
    "diagnosticTestLabel": "Diagnostic Test",
    "treatment": "Treatment",
    "parameter": "Parameter",
    "lowValue": "Low Value",
    "highValue": "High Value",
    "defaultValue": "Default Value",
    "justification": "Justification",
    "sources": "Sources",
    "testName": "Test Name",
    "defaultSensitivity": "Default Sensitivity",
    "defaultSpecificity": "Default Specificity",
    "justificationText": "Justification text",
    "sourcesJustification": "Sources/ justification",
    "reset": "Reset Selections",
    "exportSVG": "Export SVG",
    "exportPNG": "Export PNG",
    "results": "Results",
    "scenarioAssumption": "Scenario Assumptions",
    "search": "Search",
    "noDataAvailable": "NO DATA AVAILABLE",
    "noData": "No data",
    "years": "Year(s)",
    "test": "test",
    "contactUs": "Contact Us",
    "contactus": "contact us",
    "numberFormat": "{{value}}",
    "enterValue": "Enter Value",
    "population": "Population",
    "sensitivity": "Sensitivity",
    "specificity": "Specificity",
    "term": "Term",
    "definition": "Definition",
    "and": "and",
    "graphs": "Graphs",
    "tables": "Annual Tables",
    "monthlyTables": "Monthly Tables",
    "programTables": "Program Tables",
    "El": "",
    "NA": "NA"
  },
  "runScenario": {
    "title": "Run Scenario",
    "fieldRequired": "All fields are required",
    "epidemiological": "Epidemiological Context",
    "epidemiologicalTitle": "Explore epidemiological outcomes for target populations with our screening impact assessment tool.",
    "numPeople": "Number of people in target population for cervical screening",
    "numPeopleInfo": "Enter targeted number of people in the population eligible for cervical screening - Only numbers allowed as input, no commas or periods.",
    "prevelance": "Prevalence of CIN2/3 in population for cervical screening",
    "prevelanceInfo": "Enter number of women with CIN2/3 per 100 people in the population eligible for cervical screening",
    "hpvPrevelanceInfo": "Enter number of HPV prevelance",
    "numberWomenWithCin": "Enter number of women with CIN2/3 per 100 people in the population eligible for cervical screening",
    "strategySelectionTitle": "Strategy Selection",
    "strategyChoosen": "Please choose strategies to include in your scenario ",
    "byCheckingTheStrategyCheckbox": "by checking the strategy checkbox.",
    "participationTitle": "Participation in Health Services",
    "participationWarning": "Please enter the observed or anticipated participation in the cervical cancer screening program in your setting",
    "intervalofCervicalInYears": "Interval of cervical screening in years",
    "intervalInformation": "If people have one screening in a lifetime, enter 20 years. For two cervical screenings in a lifetime, enter 10 years.",
    "percentScreeningCoverage": "Percent screening coverage",
    "percentScreeningPositiveWithTriage": "Percent of screen positives with triage test",
    "percentTriagePositiveWithDiagnostic": "Percent of triage positives with diagnostic test",
    "percentDiagnosticPositiveTreated": "Percent of diagnostic test positives treated",
    "screeningAndTreatmentTitle": "Screening Strategy Characteristics",
    "screeningAndTreatmentWarning": "Please select the screening, triage and diagnostic tests and treatment modality you will use and enter an estimate of their performance characteristics.",
    "cervicalScreeningTestChosen": "Cervical screening test chosen",
    "selectTest": "Select a test",
    "sensitivity": "sensitivity",
    "specificity": "specificity",
    "screeningTestSenvitivity": "Screening test <a href='/#/about#sensitivity' target='_blank'>sensitivity</a> for CIN2/3",
    "screeningTestSenvitivity0": "Screening test ",
    "screeningTestSenvitivity1": " for CIN2/3",
    "screeningTestSpecificity": "Screening test <a href='/#/about#specificity' target='_blank'>specificity</a> for CIN2/3",
    "triageTestChosen": "Triage test chosen",
    "triageTestSensitivity": "Triage test <a href='/#/about#sensitivity' target='_blank'>sensitivity</a> for CIN2/3",
    "triageTestSpecificity": "Triage test <a href='/#/about#specificity' target='_blank'>specificity</a> for CIN2/3",
    "triageOrDiagnosticTestChosen": "Triage or diagnostic test chosen",
    "triageOrDiagnosticTestSensitivity": "Triage or diagnostic test <a href='/#/about#sensitivity' target='_blank'>sensitivity</a> for CIN2/3",
    "triageOrDiagnosticTestSpecificity": "Triage or diagnostic test <a href='/#/about#specificity' target='_blank'>specificity</a> for CIN2/3",
    "diagnosticTestChosen": "Diagnostic test chosen",
    "diagnosticTestSensitivity": "Diagnostic test <a href='/#/about#sensitivity' target='_blank'>sensitivity</a> for CIN2/3",
    "diagnosticTestSpecificity": "Diagnostic test <a href='/#/about#specificity' target='_blank'>specificity</a> for CIN2/3",
    "ScreenTreat": "Percent of screen positives treated",
    "ScreenDiagnosticTestTreat": "Percent of screening or triage/diagnostic test positives treated",
    "ScreenTriageDiagnosticTestTreat": "Percent of screen positives with triage/diagnostic test",
    "percentofScreenPositivesWithDiagnostic": "Percent of screen positives with diagnostic test",
    "PapTest": "Pap test",
    "VIA": "VIA",
    "HPV": "HPV",
    "HPV1618": "HPV16/18",
    "HPV1618Genotyping": "HPV16/18 genotyping",
    "impressionOfColposcopy": "Impression of colposcopy",
    "colposcopyWithBiopsy": "Colposcopy with biopsy",
    "cervicalTestChosen": "Cervical screening test chosen",
    "screeningCoverage": "Screening coverage",
    "pleaseRefer": "Please refer to the <a href='/#/about'  target='_blank'>About</a> tab for more information about the below parameters before entering a scenario.",
    "proportionOfPositives": "Proportion of Positives Including HPV 16/18",
    "proportionOfPositivesInfo": ""
  },
  "results": {
    "screenDiagnosisTreatment": "Screening → Diagnosis → Treatment",
    "screenTriageTreatment": "Screening → Triage → Treatment",
    "screenTriageDiagnosisTreatment": "Screening → Triage → Diagnosis → Treatment",
    "screenTreatment": "Screening → Treatment",
    "interventionsRequired": "Other interventions required in on year",
    "screeningBarChartTitle0": "Screening interventions required in one year",
    "populationWithPrecancer": "Population with precancer in one year",
    "populationWithoutPrecancer": "Population without precancer in one year",
    "precancersTreated.": "Precancers Treated",
    "annualTargets": "Annual Targets",
    "monthlyTargets": "Average Monthly Targets",
    "targets": "Program Targets",
    "populationTargetedWithCoverageTitle": "Population targeted for screening with 100% coverage",
    "populationTargetedWithoutPrecancer": "Population targeted for screening without Precancer",
    "populationTargetedWithPrecancer": "Population targeted for screening with Precancer",
    "annualImpactOnCervicalPrecancerTitle": "Annual Impact on Cervical Precancer and Impact on the Population Targeted for Screening",
    "impactOnCervicalPrecancerTitle": "Program Impact on Cervical Precancer and Impact on the Population Targeted for Screening",
    "monthlyImpactOnCervicalPrecancerTitle": "Average Monthly Impact",
    "percentPrecancersTreated": "Percent precancers treated",
    "percentPolulationTargetedOverTreated": "Percent of population targeted for screening without precancer and possibly over-treated",
    "AnnualMissedPrecancersTitle": "Annual Missed Precancers",
    "missedPrecancersTitle": "Missed Precancers",
    "programMissedPrecancersTitle": "Program Missed Precancers",
    "annualMissedPrecancersTitle": "Annual Missed Precancers",
    "monthlyMissedPrecancersTitle": "Average Monthly Missed Precancers",
    "totalPrecancersMissed": "Total precancers missed (% of all precancers)",
    "sourcesMissedPrecancers": "Sources of missed precancers (% missed precancers)",
    "didNotHaveScreeningTest": "Did not have screening ",
    "sensitivityOfScreeningTest": "<a href='/#/about#sensitivity' target='_blank'>Sensitivity</a> of screening",
    "lossAtTriageTest": "Loss at triage ",
    "sensitivityOfTriageTest": "<a href='/#/about#sensitivity' target='_blank'>Sensitivity</a> of triage ",
    "lossAtTriageDiagnosticTest": "Loss at triage/diagnosis ",
    "sensitivityOfTriageDiagnosticTest": "Sensitivity of triage/diagnosis ",
    "lossAtDiagnosis": "Loss at diagnosis",
    "sensitivityOfDiagnosticTest": "<a href='/#/about#sensitivity' target='_blank'>Sensitivity</a> of diagnosis ",
    "lossAtTreatment": "Loss at treatment",
    "AnnualImpactOnResourcesTitle": "Annual Impact on Resources",
    "impactOnResourcesTitle": "Program Impact on Resources",
    "monthlyImpactOnResourcesTitle": "Monthly Impact on Resources",
    "totalRequiringScreeningTest": "Total requiring screening test",
    "totalRequiringTriageDiagnosticTest": "Total requiring triage/diagnosis test",
    "totalRequiringDiagnosticTest": "Total requiring diagnosis test",
    "totalRequiringTreatment": "Total requiring treatment",
    "saveScenario": "Save scenario",
    "exportResultsToPDF": "Export Results to PDF",
    "exportResultsToExcel": "Export Results to Excel",
    "pPrecencersMissed": "% Precancers Missed",
    "pPrecencersTreated": "% Precancers Treated",
    "pPrecencersOverTreated": "% Precancers Over-Treated",
    "populationNotOverTreated": "Population Not-Overtreated",
    "resultGraphDefinition": "These results reflect the anticipated resources, people screened, and estimated preventive impact each year given the indicated program screening interval. Note that the preventive impact reflects one single round of screening and not the accumulated impact of repeat screening over a lifetime.",
    "resultGraphDefinition1": "Screening interventions required each year",
    "resultGraphDefinition2": "Other interventions required each year",
    "resultGraphDefinition3": "Percent of individuals screened per year who are assumed to have precancer*",
    "resultGraphDefinition4": "Percent of individuals screened per year who are assumed to not have precancer*",
    "resultGraphDefinition5": "*based on input of precancer prevalence in simulator",
    "Approximately": "Approximately",
    "screeningTests": "screening tests",
    "triageTests": "triage tests",
    "resultsDes0": "diagnostic tests will be required.",
    "resultsDes1": "women will require treatment.",
    "resultsDes2": "of women are possibly overtreated.",
    "resultsInterpretation": "Results Interpretation"
  },
  "compareScenarios": {
    "uploadScenariosInfo": "Upload up to {{limit}} scenarios for comparison. Files must be of the “.scenario” file format. Click the title of the scenario to rename it.",
    "addScenario": "Add Scenario",
    "asssumptions": "Assumptions",
    "triageorDiagnosticTestAttendance": "Triage or diagnostic test attendance",
    "diagnosticTestAttendance": "Diagnostic test attendance",
    "treatmentAttendance": "Treatment attendance"
  },
  "about": {
    "title": "Description and sources for scenario parameters",
    "prevalenceJustitication": "Population-based prevalence studies suggest 1-3% prevalence, depending upon previous screening history and immunocompetency challenges in the population.",
    "prevalenceSources0": "Zhao FH, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer. 2012 Dec 15;131(12):2929-38. ",
    "prevalenceSources1": "Ting J, et al.  A global review of age-specific and overall prevalence of cervical lesions. Int J Gynecol Cancer. 2010 Oct;20(7):1244-9. doi: 10.1111/igc.0b013e3181f16c5f. PMID: 21495248.",
    "prevalenceSources2": "Vesco KK et al. Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 May. Report No.: 11-05156-EF-1. PMID: 22132428.",
    "prevalenceSources3": "Web Annex A. Syntheses of evidence. In: WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.",
    "prevalenceSources4": "Denny L, et al.  Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA. 2005 Nov 2;294(17):2173-81.",
    "prevalenceSources5": "Herrero R, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis. 2005 Jun 1;191(11):1796-807.",
    "prevalenceSources6": "Sankaranarayanan R, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009 Apr 2;360(14):1385-94.",
    "prevalenceSources7": "Kulasingam SL, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002 Oct 9;288(14):1749-57.",
    "prevalenceSources8": "Wright TC Jr, et al. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012 Jan;206(1):46.e1-46.e11.",
    "intervalofCervicalInYearsJustification0": "Cervical cancer screening guidelines recommend screening no more frequently than every 3 years. Typically, screening intervals range from every 3 or 5 years to every 10 years, depending upon test sensitivity and feasibility to implement screening and follow-up within the health system while maintaining adequate coverage.When considering a once-in-a-lifetime screening approach, enter the value “40”, when considering a twice-in-a-lifetime approach, enter the value “20.”",
    "intervalofCervicalInYearsJustification1": "WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.",
    "intervalofCervicalInYearsJustification2": "Fontham ETH, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321-346. doi:10.3322/caac.21628",
    "intervalofCervicalInYearsJustification3": "Curry SJ, et al. Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Aug 21;320(7):674-686.",
    "percentScreeningCoverageJustification": " This metric refers to the percent of the population that you aim to reach over the course of their lifetime. Screening coverage varies widely by country, geographic region, resource setting, and population.",
    "percentScreeningCoverageSource": "Bruni L, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Health. 2022 Aug;10(8):e1115-e1127.",
    "percentScreeningPositiveTriageDiagnosticsJustification": "This metric refers to the percent of those with an abnormal screening result that will receive the subsequent triage or diagnostic test. Follow-up rates vary widely between 25-99%, depending on resources and contexts.",
    "percentScreeningPositiveTriageDiagnosticsSource": "Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, Poljak M, Murillo R, Broutet N, Riley LM, de Sanjose S. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Health. 2022 Aug;10(8):e1115-e1127. doi: 10.1016/S2214-109X(22)00241-8. PMID: 35839811; PMCID: PMC9296658.",
    "percentTriageDiagnosticTestPositivesJustification": "This metric refers to the percent of those with an abnormal triage or diagnostic test that will receive treatment. Follow-up rates vary widely between 25-99%, depending on resources and contexts. Screen-and-treat programs tend to have better follow-up with treatment due to fewer steps in management.",
    "percentScreeningPositivesTriageJustification": " This metric refers to the percent of those with an abnormal result that will receive the triage/diagnostic test. Follow-up rates vary widely between 25-99%, depending on resources and contexts.",
    "percentScreeningPositivesDiagnosisJustification": "This metric refers to the percent of those with an abnormal result that will receive the triage/diagnostic test. Follow-up rates vary widely between 25-99%, depending on resources and contexts.",
    "percentDiagnosticPositivesTreatedJustification": "This metric refers to the percent of those with an abnormal result that will receive treatment. Follow-up rates vary widely between 25-99%, depending on resources and contexts.",
    "percentTriageDiagnosticTestPositivesSource0": "Murillo, R., et al., Cervical cancer screening programs in Latin America and the Caribbean. Vaccine, 2008. 26 Suppl 11: p. L37-48.",
    "percentTriageDiagnosticTestPositivesSource1": "Sankaranarayanan R, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009 Apr 2;360(14):1385-94.",
    "percentTriageDiagnosticTestPositivesSource2": "Campos NG, Maza M, Alfaro K, Gage JC, Castle PE, Felix JC, Cremer ML, Kim JJ. The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador. Int J Cancer. 2015 Aug 15;137(4):893-902. doi: 10.1002/ijc.29438. Epub 2015 Feb 3. PMID: 25639903.",
    "papTestJustification": "Pap test performance varies widely across settings. Sensitivity can range from 25-75%, with most estimates 50-70%",
    "papTestSource0": "Arbyn M, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 2008; 123: 153-160.",
    "papTestSource1": "Cuzick J, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. IJC.2006;119:1095–1101.",
    "papTestSource2": "Mayrand HM, et al. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. NEJM 2007;357:1579-1588.",
    "papTestSource3": "Almonte et al. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. IJC 121, 706-802, 2007.",
    "papTestSource4": "Nanda K et al. Ann Intern Med 2000",
    "papTestSource5": "Web Annex A. Syntheses of evidence. In: WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization",
    "viaJustification": "Estimates vary wide and depend on training and continued quality control. Global average about 65% sensitivity and 87% specificity. Estimates of test performance following a positive HPV test are similarly wide.",
    "hpvJustification": "Estimates of HPV test performance in screening programs are less variable.",
    "hpvSource1": "Cuzick J, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. IJC.2006;119:1095–1101.",
    "impressionOfColposcopyJustification": "Accuracy of colposcopic impression varies widely with significant bias. Most estimates of sensitivity are 50-80% while estimates of specificity are 70-95%.",
    "impressionOfColposcopySource": "Brown BH, Tidy JA. The diagnostic accuracy of colposcopy - A review of research methodology and impact on the outcomes of quality assurance. Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:182-186. doi: 10.1016/j.ejogrb.2019.07.003. Epub 2019 Jul 3. PMID: 31302386.",
    "sensitivity": "The percent of the population with precancer/cancer that have a positive test result.",
    "specificity": "The percent of the population without precancer/cancer that have a negative test result.",
    "aboutWhoTile": "WHO Cervical Cancer Elimination Initiative Guidance",
    "aboutDes0": "WHO Strategy to Accelerate the Elimination of Cervical Cancer as a Global Public Health Problem",
    "aboutDes1": "The goal of the WHO Cervical Cancer Elimination Initiative is for all countries to reach and maintain an incidence rate of below 4 per 100 000 women. Achieving that goal rests on three key pillars and their corresponding targets:",
    "aboutDes2": "vaccination: 90% of girls fully vaccinated with the HPV vaccine by the age of 15;",
    "aboutDes3": "screening: 70% of women screened using a high-performance test by the age of 35, and again by the age of 45;",
    "aboutDes4": "treatment: 90% of women with pre-cancer treated and 90% of women with invasive cancer managed.",
    "aboutDes5": "Each country will reach the elimination goals at their own pace according to competing priorities, available resources, and planning.",
    "aboutDes6": "Link to: ",
    "aboutDes7": " https://www.who.int/initiatives/cervical-cancer-elimination-initiative",
    "hpvPrevelence": "HPV Prevalence",
    "overTreated": "Overtreated",
    "overTreatment": "Overtreatment",
    "overTreatedDef": " In a cervical cancer screening program, overtreatment occurs to some extent because a proportion of the people treated have precancer* not destined to progress or some individuals might be treated for a false-positive diagnosis of cervical precancer. Overtreatment can result in side effects and complications, including psychological harms and resource implications. This tool uses the \"overtreatment\" in a simplified sense and recognizes that the importance and implications of overtreatment may vary by context.",
    "prevalenceSources9": "de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007 Jul;7(7):453-9. doi: 10.1016/S1473-3099(07)70158-5. PMID: 17597569.",
    "prevalenceSources10": "Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, Clifford GM. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012 Nov 15;131(10):2349-59. doi: 10.1002/ijc.27485. Epub 2012 Mar 20. PMID: 22323075.",
    "prevalenceSourcesJustification": "The prevalence of HPV is highly variable by age, immune status and geography. For women age 30-49, the prevalence is generally around 11-12%. For women under age 25, HPV prevalence is typically much higher, and infections usually resolve within one year. Given geographic variations, we encourage users who do not know the HPV prevalence in their setting to use prevalence estimates based upon observed results among women of similar age in local screening programs or neighboring countries. This tool is not meant for HIV-endemic populations due to variations in HPV epidemiology.",

    "": ""
  }
}
